Proteomic profiles of human lung adeno and squamous cell carcinoma using super-SILAC and label-free quantification approaches

Proteomics

Volumn 14, Issue 6, 2014, Pages 795-803

  Zhang, Wen ^a,b   Wei, Yuhong ^a   Ignatchenko, Vladimir ^c   Li, Lei ^a   Sakashita, Shingo ^b,c   Pham, Nhu An ^c   Taylor, Paul ^a   Tsao, Ming Sound ^b,c   Kislinger, Thomas ^b,c   Moran, Michael F ^a,b,c  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Biomedicine; Label free; Lung cancer; Shotgun proteomics; Super SILAC; Xenograft

Indexed keywords

ARGININE; BEVACIZUMAB; BIOLOGICAL MARKER; CARBON 13; CISPLATIN; CYTOKERATIN; DOXORUBICIN; ISOTOPE; LYSINE; MESSENGER RNA; MUCIN; NITROGEN 15; PEMETREXED; PHOSPHOGLYCERATE DEHYDROGENASE; PROTEIN; PROTEOME;

ARTICLE; BIOMEDICINE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; ISOTOPE LABELING; LABEL FREE SHOTGUN PROTEOMICS; LIQUID CHROMATOGRAPHY; LUNG ADENOCARCINOMA; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ANALYSIS; SHOTGUN PROTEOMICS; TREATMENT RESPONSE; TUMOR XENOGRAFT;

BIOMEDICINE; LABEL-FREE; LUNG CANCER; SHOTGUN PROTEOMICS; SUPER-SILAC; XENOGRAFT;

ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; HUMANS; LUNG; LUNG NEOPLASMS; PROTEOME; PROTEOMICS; TANDEM MASS SPECTROMETRY;

EID: 84895760967     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201300382     Document Type: Article

References (48)

1. American Cancer Society. Cancer Facts & Figures 2012. Atlanta: American Cancer Society; 2012.
2. Hirsch, F. R., Spreafico, A., Novello, S., Wood, M. D. et al., The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. J. Thorac. Oncol. 2008, 3, 1468-1481.
3. Neal, J. W., Histology matters: individualizing treatment in non-small cell lung cancer. Oncologist 2010, 15, 3-5.
4. Johnson, D. H., Fehrenbacher, L., Novotny, W. F., Herbst, R. S. et al., Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 2004, 22, 2184-2191.
5. Scagliotti, G., Brodowicz, T., Shepherd, F. A., Zielinski, C. et al., Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J. Thorac. Oncol. 2011, 6, 64-70.
6. Garber, M. E., Troyanskaya, O. G., Schluens, K., Petersen, S. et al., iversity of gene expression in adenocarcinoma of the lung. Proc. Natl. Acad. Sci. USA 2001, 98, 13784-13789.
7. Kikuchi, T., Daigo, Y., Katagiri, T., Tsunoda, T. et al., Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene 2003, 22, 2192-2205.
8. Bhattacharjee, A., Richards, W. G., Staunton, J., Li, C. et al., Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc. Natl. Acad. Sci. USA 2001, 98, 13790-13795.
9. Hou, J., Aerts, J., den Hamer, B., van Ijcken, W. et al., Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PloS ONE 2010, 5, e10312.
10. Schwanhausser, B., Busse, D., Li, N., Dittmar, G. et al., Global quantification of mammalian gene expression control. Nature 2011, 473, 337-342.
11. Chen, G., Gharib, T. G., Huang, C. C., Taylor, J. M. et al., Discordant protein and mRNA expression in lung adenocarcinomas. Mol. Cell. Proteomics 2002, 1, 304-313.
12. Wei, Y., Tong, J., Taylor, P., Strumpf, D. et al., Primary tumor xenografts of human lung adeno and squamous cell carcinoma express distinct proteomic signatures. J. Proteome Res. 2011, 10, 161-174.
13. Kikuchi, T., Hassanein, M., Amann, J. M., Liu, Q. et al., In-depth proteomic analysis of nonsmall cell lung cancer to discover molecular targets and candidate biomarkers. Mol. Cell. Proteomics 2012, 11, 916-932.
14. Aebersold, R., Mann, M., Mass spectrometry-based proteomics. Nature 2003, 422, 198-207.
15. Ong, S. E., Mann, M., Mass spectrometry-based proteomics turns quantitative. Nat. Chem. Biol. 2005, 1, 252-262.
16. Geiger, T., Cox, J., Ostasiewicz, P., Wisniewski, J. R., Mann, M., Super-SILAC mix for quantitative proteomics of human tumor tissue. Nat. Methods 2010, 7, 383-385.
17. John, T., Kohler, D., Pintilie, M., Yanagawa, N. et al., The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer. Clin. Cancer Res. 2011, 17, 134-141.
18. Wisniewski, J. R., Zougman, A., Nagaraj, N., Mann, M., Universal sample preparation method for proteome analysis. Nat. Methods 2009, 6, 359-362.
19. St-Germain, J. R., Taylor, P., Tong, J., Jin, L. L. et al., Multiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibition. Proc. Natl. Acad. Sci. USA 2009, 106, 20127-20132.
20. Cox, J., Mann, M., MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 2008, 26, 1367-1372.
21. Cox, J., Neuhauser, N., Michalski, A., Scheltema, R. A. et al., Andromeda: a peptide search engine integrated into the MaxQuant environment. J. Proteome Res. 2011, 10, 1794-1805.
22. Vizcaíno, J. A., Côté, R. G., Csordas, A., Dianes, J. A. et al., The PRoteomics IDEntifications (PRIDE) database and associated tools: status in 2013. Nucleic Acids Res. 2013, 41, D1063-D1069.
23. Deeb, S. J., D'Souza, R. C., Cox, J., Schmidt-Supprian, M., Mann, M., Super-SILAC allows classification of diffuse large B-cell lymphoma subtypes by their protein expression profiles. Mol. Cell. Proteomics 2012, 11, 77-89.
24. Taylor, P., Nielsen, P. A., Trelle, M. B., Horning, O. B. et al., Automated 2D peptide separation on a 1D nano-LC-MS system. J. Proteome Res. 2009, 8, 1610-1616.
25. Kislinger, T., Cox, B., Kannan, A., Chung, C. et al., Global survey of organ and organelle protein expression in mouse: combined proteomic and transcriptomic profiling. Cell 2006, 125, 173-186.
26. Rugg-Gunn, P. J., Cox, B. J., Lanner, F., Sharma, P. et al., Cell-surface proteomics identifies lineage-specific markers of embryo-derived stem cells. Dev. Cell 2012, 22, 887-901.
27. Cox, J., Matic, I., Hilger, M., Nagaraj, N. et al., A practical guide to the MaxQuant computational platform for SILAC-based quantitative proteomics. Nat. Protocols 2009, 4, 698-705.
28. Gortzak-Uzan, L., Ignatchenko, A., Evangelou, A. I., Agochiya, M. et al., A proteome resource of ovarian cancer ascites: integrated proteomic and bioinformatic analyses to identify putative biomarkers. J. Proteome Res. 2008, 7, 339-351.
29. Fermin, D., Basrur, V., Yocum, A. K., Nesvizhskii, A. I., Abacus: a computational tool for extracting and pre-processing spectral count data for label-free quantitative proteomic analysis. Proteomics 2011, 11, 1340-1345.
30. Choi, H., Fermin, D., Nesvizhskii, A. I., Significance analysis of spectral count data in label-free shotgun proteomics. Mol. Cell. Proteomics 2008, 7, 2373-2385.
31. Chen, Y., Cui, T., Yang, L., Mireskandari, M. et al., The diagnostic value of cytokeratin 5/6, 14, 17, and 18 expression in human non-small cell lung cancer. Oncology 2011, 80, 333-340.
32. Terry, J., Leung, S., Laskin, J., Leslie, K. O. et al., Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. Am. J. Surg. Pathol. 2010, 34, 1805-1811.
33. Moll, R., Divo, M., Langbein, L., The human keratins: biology and pathology. Histochem. Cell Biol. 2008, 129, 705-733.
34. Pizzi, M., Fassan, M., Balistreri, M., Galligioni, A. et al., Anterior gradient 2 overexpression in lung adenocarcinoma. Appl. Immunohistochem. Mol. Morphol. 2102, 2, 63-13.
35. Wang, Z., Hao, Y., Lowe, A. W., The adenocarcinoma-associated antigen, AGR2, promotes tumor growth, cell migration, and cellular transformation. Cancer Res. 2008, 68, 492-497.
36. Lin, Y. C., Shun, C. T., Wu, M. S., Chen, C. C., A novel anticancer effect of thalidomide: inhibition of intercellular adhesion molecule-1-mediated cell invasion and metastasis through suppression of nuclear factor-kappaB. Clin. Cancer Res. 2006, 12, 7165-7173.
37. Pierce, A., Barron, N., Linehan, R., Ryan, E. et al., Identification of a novel, functional role for S100A13 in invasive lung cancer cell lines. Eur. J. Cancer 2008, 44, 151-159.
38. Possemato, R., Marks, K. M., Shaul, Y. D., Pacold, M. E. et al., Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 2011, 476, 346-350.
39. Locasale, J. W., Grassian, A. R., Melman, T., Lyssiotis, C. A. et al., Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat. Genet. 2011, 43, 869-874.
40. Deleo, A. B., Targeting cancer stem cells with ALDH1A1-based immunotherapy. Oncoimmunology 2012, 1, 385-387.
41. Ginestier, C., Hur, M. H., Charafe-Jauffret, E., Monville, F. et al., ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1, 555-567.
42. Douville, J., Beaulieu, R., Balicki, D., ALDH1 as a functional marker of cancer stem and progenitor cells. Stem Cells Dev. 2009, 18, 17-25.
43. Wu, A., Luo, W., Zhang, Q., Yang, Z. et al., Aldehyde dehydrogenase 1, a functional marker for identifying cancer stem cells in human nasopharyngeal carcinoma. Cancer Lett. 2013, 330, 181-189.
44. Shien, K., Toyooka, S., Yamamoto, H., Soh, J. et al., Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells. Cancer Res. 2013, 73, 3051-3061.
45. Huang, C. P., Tsai, M. F., Chang, T. H., Tang, W. C. et al., ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors. Cancer Lett. 2013, 328, 144-151.
46. Ai, L., Kim, W. J., Demircan, B., Dyer, L. M. et al., The transglutaminase 2 gene (TGM2), a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer. Carcinogenesis 2008, 29, 510-518.
47. Park, K. S., Kim, H. K., Lee, J. H., Choi, Y. B. et al., Transglutaminase 2 as a cisplatin resistance marker in non-small cell lung cancer. J. Cancer Res. Clin. Oncol. 2010, 136, 493-502.
48. Liu, N. Q., Dekker, L. J., Stingl, C., Guzel, C. et al., Quantitative proteomic analysis of microdissected breast cancer tissues: comparison of label-free and SILAC-based quantification with shotgun, directed, and targeted MS approaches. J. Proteome Res. 2013, 12, 4627-4641.